



Deloitte.

Next generation
"smart" MedTech devices
Preparing for an increasingly
intelligent future

Audit. Tax. Consulting. Financial Advisory.

Executive summary

Exponential technological progress is advancing scientific knowledge, reducing costs, and presenting the health care and life sciences marketplace with innovative medical devices and procedures that diagnose, monitor, and treat patient conditions. Five important building blocks of exponential technological progress are:

- Increased computing power
- Large data storage capacity
- Hardware miniaturisation
- Network connectivity
- Advance software capability

Many industry players – both traditional medical technology (MedTech) organisations and new market entrants – are capitalising on recent and emerging technological advancements and providing novel health care solutions using mobile health (mHealth) applications, sensor technology, data analytics, and artificial intelligence. Venture capital investments, which fuel development of innovative MedTech products, have grown steadily over the last decade, especially in the areas of bioinformatics and biosensors.

Four shifts will likely shape the new health care landscape and drive opportunities for “smart” MedTech:

- Shift from acute to preventive care, specialists to self-care, and hospital to home care. More services will likely take place in non-traditional health care settings. Consumers with remote access to data through smart devices can manage their own care conditions.
- Shift from monitoring single biometric indicators to multiple indicators, processed through artificial intelligence. This can provide true health insights.
- Shift from intuitive approaches based on empirical evidence for typical patients to precision-based health care rooted in the individual patient’s characteristics. This can allow physicians to harness information from intelligent algorithms to inform treatment decisions.

- Shift from specialised silos of medical knowledge to more centralised and accessible knowledge centres. This can allow clinicians to provide sophisticated care without necessarily having specialized training.

Innovative smart MedTech device companies are anticipated to contribute to and capitalise on these market shifts. Traditional players, meanwhile, may lose revenue and market share if they do not develop consumer-centric products and end-to-end solutions with an eye to these shifts. MedTech companies should consider continuously monitoring and evaluating their competitors’ activities, especially those which are driving technological innovation. They should consider leveraging large data pools in place of small data puddles to capture true insights. Finally, MedTech companies should consider identifying partners, alliances, and other collaborative opportunities to acquire the capabilities and expertise they may need to develop next-generation MedTech devices and thrive in this new environment.



Introduction

Star Trek fans may fondly remember the Tricorder, a sophisticated, hand-held device used to sense, analyse, and record information. Dr. Leonard McCoy used his Tricorder to instantaneously diagnose disease and traumatic injuries, a process that might require today's health care professionals to engage in weeks of iterative assessments, interpretations, and discussions. Fortunately, nearly five decades after *Star Trek's* debut, the use of "futuristic" devices is moving from television screens to real-world care settings.


In the early 20th century, doctors and nurses traveled to patients' homes and provided personalised, bedside care. However, that care was limited to what the practitioner knew; prevailing knowledge of effective treatments was often anecdotal and unscientific. These were the old days, when one nurse did nearly everything for the patient. With the passage of time, practitioners' knowledge grew, the health care system became increasingly complex, physicians specialised, and academic medical centres generated new discoveries.

Today, the health care landscape features ever-increasing specialisation and high costs. Numerous physician specialists and care settings typically are involved in a single patient's care (Figure 1). Physicians and other care providers often retain data in silos and do not or cannot share information, especially not in real time.¹

The future scenario looks different. Technology that leverages scientific advances, the proliferation of low-cost sensors, and the power of the Internet may allow providers and patients to more efficiently gather and disseminate information. Data collected and run through intelligent algorithms might enable physicians and nurses to coordinate and integrate care delivery and provide real-time feedback and actionable information to their patients and other providers. We can imagine a future, as *Star Trek* creator Gene Rodenberry did, in which anyone can use a high-tech, all-in-one medical device – like a Tricorder – to diagnose, monitor, and treat disease. In this future reality, "smart" MedTech would simplify and improve medical care, harnessing information from intelligent algorithms built into devices to process biometric data and support treatment decisions. We might even go so far as to envision an updated version of the "did-it-all" model – one person could handle all of a patient's care, but he or she would be armed with more insights into the patient's condition.

This future may not be very far away. Technology is evolving rapidly and evidence of work towards a Tricorder-like device already exists. The XPrize Foundation,² an organisation that aims to spur innovation by offering cash incentives, has launched a large-scale effort to develop a consumer-friendly, all-inclusive MedTech device.

Figure 1. Health care complexity has grown exponentially; in the future, technology will likely support simplification



Source: Deloitte analysis

One example of a smart MedTech device that shows early promise and potential savings is the artificial pancreas, a technology that links an insulin pump with a continuous glucose monitor to provide automatic, real-time monitoring of glucose levels and insulin delivery. A study found that the artificial pancreas could generate potential savings of \$1.9 billion for the US Medicare program in over twenty five years.³

Evolution of exponentials, accelerating returns will aid development

Moore's Law, authored in 1965 and updated in 1995 by Gordon Moore, co-founder of Intel Corporation, states that the number of transistors on a computer microchip would double every two years.⁴ This law has become the guiding principle for the industry to deliver ever-more-powerful semiconductor chips at proportionate decrease in cost. Building on this concept, noted author and futurist Ray Kurzweil states in his law of accelerating returns that the pace of technological change and information embedded in the technology advances exponentially, not linearly.⁵ Kurzweil also posits that the pace of exponential growth is itself growing exponentially; moreover, within the next few decades, he predicts machine intelligence will likely surpass human intelligence, leading to what is called The Singularity.

Moore's and Kurzweil's laws tell us that we should expect increasing returns from powerful supercomputers, such as IBM's Watson. Supercomputers are anticipated to lead the way towards personalised medicine, performing big-data analytics and helping physicians diagnose problems, target medications, and develop care plans based on a huge global knowledge base. As evidence, Watson's successful diagnosis rate for lung cancer is 90 percent, compared with 50 percent for human doctors.⁶ In the future, remote access to supercomputers could be extended beyond physicians and other medical professionals to consumers, aiding their use of online resources (e.g. planetesante.ch, revmed.ch, doctissimo.fr, netdokter.de, WebMD.com) to obtain information about their own conditions.

In another example of accelerating returns, sensor-enabled devices are getting faster, cheaper, and smaller, and being embedded into everyday activities. Sensors have automated high-end homes for years, but sensors for medical applications – called biosensors – can monitor biological and other processes. In addition to motion, light, pressure, temperature, moisture, and gas, biosensors may be able to monitor chemicals and biomarkers. For example, doctors may be able to use biosensors to determine how well a drug is metabolised and adjust the dosage and frequency accordingly. Biosensors can be placed in a watch, a patch on the skin (e.g., movement patch sensors from Gentag and Mayo Clinic),⁷ implanted under the skin, or swallowed like a pill.


As computing power continues to follow the path of Moore's Law, a personal computer of 2050 might have more processing capability than all of the human minds in the world combined.⁸

The frontiers of MedTech

Smart MedTech has the potential to increase the value of information in medical care. As illustrated (Figure 2), improved sensor technologies allow us to **create** information from previously unobserved actions in the human body, both chemical and mechanical, while better wireless technologies allow us to **communicate** it economically. We can **aggregate** data in almost limitless volumes over time and across data sources – although

the absence of technical standards and the legal and regulatory frameworks governing data sharing limit who has access to what information. Cognitive technologies such as artificial intelligence allow us to **analyse** data in quantities and ways that reveal more effective responses. This can lead to changes in how we **act** – and the cycle repeats. The connection between action, information, and changes in action is captured in the graphic shown here.

Figure 2. The information value loop



Source: Deloitte analysis

Five building blocks of exponential technological progress


Five important building blocks of exponential technological progress are computing power, data storage, network connectivity, miniaturised hardware, and advanced software. As MedTech companies and other organisations experiment with these building blocks, the pace of technological development will likely increase. Moreover, the cost of technologies relative to their performance continues to shrink, as illustrated by Deloitte’s analysis of the core technologies of computing power, data storage, and bandwidth.

Computing power – The cost of computing power has decreased significantly, from \$222 per million transistors in 1992 to \$0.06 per million transistors in 2012 (Figure 3). This cost-performance trend enables greater computational power at the core of the digital infrastructure.⁹ Also, computing in three dimensions is beginning to emerge; for example, through 3D microchips. Inventors are developing three-dimensional circuits that can operate at the molecular level (e.g., carbon nanotubes, where hexagonal arrays of carbon atoms are organized to form electronic circuits).¹⁰


Data storage – Data storage capacity has grown by leaps and bounds over the last five decades and the cost of data storage has decreased considerably, from \$569 per gigabyte (GB) of storage in 1992 to \$0.03 per GB in 2012 (Figure 3). This cost-performance trend for digital storage may support richer digital information.¹¹ As evidence, the human brain’s storage capacity is estimated at around one to 10 terabytes, and hard drives at this size are already available to consumers. With new, higher-density storage formats (e.g., carbon nanotubes, that arrange components atom-by-atom), devices can store large amounts of patient and population health data.

Bandwidth – The cost of Internet bandwidth has steadily decreased, from \$1,245 per 1,000 megabits per second (Mbps) in 1999 to \$23 per 1,000 Mbps in 2012 (Figure 3). Cheaper and faster bandwidth may enable much faster collection and transfer of data, facilitating richer connections and interactions.¹² Networks are also experiencing similar exponential advances. Advances include ultra-capacity fibre capable of more than one petabit per second,¹³ heterogeneous networks of small cells (micro, pico, and femtocells),¹⁴ terahertz radiation,¹⁵ and balloon-powered broadband in rural and remote areas. Faster access to information may support real-time decision-making by clinicians at patients’ bedsides.¹⁶

Figure 3. Computing, storage, and bandwidth cost-performance



Source: Deloitte analysis, Deloitte 2013 Shift Index series



Internet use continues to increase rapidly. From 1990 to 2012, the percentage of the US population accessing the Internet at least once a month has grown from near zero to 71 percent. Widespread use of the Internet enables more widespread sharing of information and resources. Wireless connectivity is further facilitated by smart devices, which made up 55 percent of total wireless subscriptions in 2012, compared to just one percent in 2001.¹⁷

Miniaturised hardware – We are making things smaller at a rate of 5.6 per linear dimension per decade. This trend is particularly rapid in the computer and mobile device sectors. Miniaturisation may allow MedTech companies to develop small devices that can measure multiple parameters through integration of numerous biosensors.¹⁸

Advanced software – Moore’s law also applies to software development. Fifteen years ago, for example, a \$5,000 speech recognition system could barely recognize 1,000 words of vocabulary. Today, even a \$50 system can accurately recognize 100,000 words.¹⁹

The continuing development of these five building blocks magnifies exponential advancement, offering opportunities for MedTech and other companies that are able to tap into the trends. The increasing affordability of digital technology, coupled with wireless networks and powerful mobile devices such as smartphones and tablets, has created an increasingly broad platform for users to connect and communicate anywhere and at any time. When technologies merge into open platforms and ecosystems, the investment becomes lower and lead time shorter since people and technologies can rapidly build on previous waves of development.²⁰

MedTech applications of exponential technology

Already, the MedTech sector is beginning to see evidence that innovators are developing products that take advantage of the opportunities emanating from exponential technological progress; for example, in the areas of artificial intelligence and mHealth.

Artificial Intelligence

Artificial Intelligence refers to machines doing intellectual tasks at a level comparable to humans – e.g., reasoning, planning, learning, and using natural language to communicate at a high level. Artificial intelligence also includes sensing and interacting with the physical world. According to Hans Moravec, a pioneer in artificial intelligence, a thinking machine comparable to a mature human brain will likely be available by 2020.²¹

Artificial intelligence and machine learning have moved beyond experimental concepts in many industries, including MedTech. By harnessing the speed of the Internet, the scale of cloud storage, and increasing computing power, artificial intelligence has the potential to drive insights that may aid real-time medical analytics and clinical decision-making. Artificial intelligence technologies have the potential to make health care more efficient by combining the knowledge of physicians and intelligent software.

Three important trends in artificial intelligence are cognitive analytics, clinical decision support systems, and predictive modeling. Like the human brain, machines can now learn from experience and penetrate the complexity of data to identify associations. This is called *cognitive analytics*.²² Cognitive analytics can bridge the gap between the future promise of big data – to enable new care insights gleaned through data aggregation – and the current need for practical decision-making and prompt diagnosis and response. Cognitive analytics has the potential to push past the limitations of human cognition, allowing for data processing and understanding in real time, and managing the challenge of exploding volumes of data with vastly different forms, structures, and quality.²³

IBM has partnered with Carillion Clinic, a Virginia (US) health system, to identify 8,500 patients at risk for developing heart failure. The project analyses data in electronic health records (EHRs), including unstructured data such as clinicians' notes and discharge documents that are not often analysed. Using IBM's natural language processing technology to assess and understand, these notes provide a more complete and accurate understanding of each patient.²⁴

A clinical decision support system is data analysis software that analyses patient data. It generates real-time, evidence-based recommendations to physicians, nurses, and other health care professionals, which allows them to quickly prepare a diagnosis or review the diagnosis in an effort to improve the final result. Such analysis can help to predict potential events, which can range from drug interactions to disease symptoms.

The Mayo Clinic tested clinical decision support systems that help physicians more accurately diagnose endocarditis, a type of heart infection. Tests for the condition are invasive and can be both painful and dangerous. An artificial intelligence-based system used in the study learned to correlate each patient's unique symptoms with a diagnosis and was able to determine that 50 percent of the patients did not have the infection, eliminating the need for an unnecessary and risky procedure.

Predictive modeling analyses patterns and trends in historical data to develop predictions. Together with medical knowledge and precise decision aid tools, predictive modeling offers potential to simplify the diagnosis and treatment of numerous diseases. By knowing in advance that a group of patients are at low or high risk for a disease or condition, health care providers can create targeted treatment approaches.

IBM developed a predictive solution to analyse and monitor clinician signs in premature babies. It takes real-time biomedical readings and uses them to detect life-threatening infections up to 24 hours before they would normally be observed.

mHealth

mHealth applies the power and reach of mobile communication to health care services. It plays a key role in transforming health care into a more-efficient, patient-centered system of care in which individuals (and providers) have real-time access to information to support engagement. According to Deloitte's 2015 survey of US health care consumers, 13 percent used video, a computer program, or a mobile app to learn about treatment options and 17 percent are very interested in doing so in the future. The same survey also noted that 23 percent of those with major chronic conditions use mobile apps to refill prescriptions.²⁶

The Deloitte Center for Health Solutions report, *mHealth in an mWorld*, explores how the rapid growth of mobile technology, the widespread use of mobile devices, and increasing consumer demand is underpinning the shift to a mobile-device-enabled era in health care.²⁷ Use of mHealth spans a broad spectrum of capabilities, which can be classified into three levels:

1. Basic: mHealth app with limited features; data is captured manually. Users manually input dietary intake and the application compiles reports on daily calorie, sodium, fat, and carbohydrate intake (e.g., MyFitnessPal, Nutrition Menu, and MyNetDiary).
2. Intermediate: mHealth app with limited features; data is captured via biosensors with minimal manual efforts. While still nascent, examples include an inhaler from Propeller Health with a built-in asthma sensor to measure air quality, and Biostamp, a wearable device that can monitor and transmit vital signs.
3. Advanced: mHealth app with the ability to capture multiple inputs via biosensors, coupled with intelligent data-processing capabilities. These devices are not yet widely developed; however, one example is Scanadu Scout, a portable device that measures temperature, heart rate, blood oxygen levels, respiratory rate, ECG, and blood pressure. It transmits all this information to a mobile device.



Implications for the MedTech industry

The table below provides examples of opportunities for MedTech companies to demonstrate value through next-generation MedTech devices. Across episode types – from acute to chronic to preventive care – health systems and other purchasers are looking for solutions to help them achieve better results.

Going forward, the new value proposition is for technologies that can help an organisation reduce total costs of care – for example, by preventing complications or high-cost institutional care. Also valuable are technologies that can improve health outcomes and patient experience, as new value-based payment models reward health systems that are able to do this.

Episode type	Improved value	Technology application	Technology involved	Evidence
Acute care Example: Stroke care	<ul style="list-style-type: none"> Improved cost efficiencies Improved patient outcomes Improved patient access to quality health care Improved care coordination in an emergency situation Reduced emergency room (ER) use by stabilising patient at home 	<ul style="list-style-type: none"> Live and interactive consultations from remote location Vital information sent to a receiving hospital before the patient arrives Coordination with patients after discharged from ER or intensive care unit (ICU) 	<ul style="list-style-type: none"> Telemedicine for patient monitoring 24/7 emergency response Augmented and alternative communication system Wireless technology 	<ul style="list-style-type: none"> ER visits in the US could exceed 200 million annually by 2020³¹
Post-acute care Example: Rehab after broken hip	<ul style="list-style-type: none"> Reduced hospitalisations and readmissions Increased patient satisfaction Reduced costs Improved patient health and quality of life Improved identification of care setting and providers 	<ul style="list-style-type: none"> Medication adherence Medical reconciliation Remote patient monitoring (RPM) Patient health information Social support Remote training and supervision 	<ul style="list-style-type: none"> Medical reminders and dispensers Medication list software In-home diagnostic devices Problem-detection algorithms Videoconferencing Social networks 	<ul style="list-style-type: none"> 18 percent of US hospital readmissions are within 30 days of discharge; 76 percent of these are preventable³² Over half of the readmitted patients received no care or follow-up in the 30 days after hospitalisation³³
Chronic care Example: Congestive heart failure (CHF)	<ul style="list-style-type: none"> Decreased hospital or nursing home admissions Regular feedback, motivation, and education to help patients manage their conditions and engage in healthy behaviours Easier access to care for existing patients 	<ul style="list-style-type: none"> Diffusion of communication technologies into the health care system Self-care Remote care Remote lifestyle feedback Interactive patient-provider online communication Home monitoring 	<ul style="list-style-type: none"> Connected health RPM Sensors to capture quantitative data remotely Network technologies Secure storage and processing capabilities Shared electronic health records and e-referral systems 	<ul style="list-style-type: none"> Use of RPM in the management of CHF had demonstrated a 60 percent decrease in hospital admissions; 81 percent decrease in nursing home admissions; 66 percent decrease in ER visits³⁴
Preventive care and wellness	<ul style="list-style-type: none"> Personalised alerts aimed at preventive services Accurate diagnoses and proactive recommendations for preventive treatment by physicians 	<ul style="list-style-type: none"> Tools that combine physician and patient health records Integration with insurers' large base of useful patient data Patient-specific decision support and communication Reliable technology in onsite kiosk for self diagnosis 	<ul style="list-style-type: none"> Mobile technology apps Remote monitoring device Interactive preventive health record Onsite technology Wearable sensors and personal genomics 	<ul style="list-style-type: none"> 25 percent of patients who had access to interactive preventive health records were up-to-date on all preventive services – double the rate of non-users³⁵

New players are driving technological innovation

The global MedTech market is estimated to reach \$513.5 billion by 2020, up from \$363.8 billion in 2013, with a compound annual growth rate of 5 percent.³⁶ Traditional growth drivers include an ageing population, increase in chronic disease, and emerging markets' ability to pay for MedTech. In addition, technology-specific advances – among them, computing power, data storage, network connectivity, miniaturised hardware, and software capability – have opened up other growth opportunities. New players, many from outside the MedTech space, are capitalising on these advances and driving innovation at the rapid pace of technological change.

MedTech companies should consider equipping themselves to take advantage of opportunities arising from smart technologies or risk losing business to both traditional competitors and new market entrants. Leading technology companies (e.g., Google, Apple Inc., and IBM) are a considerable threat, appearing through their product introductions to be eager to claim a portion of this burgeoning market. In addition, agile startups (e.g., startups competing to win an XPrize) pursuing growth opportunities from a “think big” perspective may quickly carve out share in niche markets.

Ability to turn information into insights may improve outcomes

The ability to capture and process vast amounts of data and turn it into actionable insights is a crucial factor for success in the rapidly changing, technology-based health care environment. Going forward, MedTech devices may need to be intelligent and user-friendly, and make wider use of biosensors. Small “data puddles” (one or a few biosensors generating data) will likely not be sufficient to drive health insights. Instead, companies may need “data pools” that combine inputs from multiple biosensors. The resulting patient data could then be processed and presented more intelligently, resulting in better levels of patient monitoring, care advancements and, improved outcomes.

New environment, new innovations require new alliances

Smart MedTech operates in a rapidly changing, fast-moving environment requiring diligent and continuous monitoring of new innovations. A Deloitte University Press report, *The three rules in medical technology*,³⁷ provides a strategic framework that MedTech companies can use to anchor their innovation strategy. Among the framework's approaches are fostering innovation internally; buying and integrating innovators; and externalising innovation by creating innovation ecosystems (via partnerships/alliances) with academic centres, venture capitalists, and startup entities.

Smart MedTech product development requires specialisation and expertise in wide-ranging fields. New partnerships and alliances can augment or replace internal design and development efforts, and help commercialize and bring products to market. When identifying potential partnerships, MedTech companies should consider the type of solution they are planning to develop (e.g., data input device or decision-making device) and then identify areas where an alliance may generate cost-saving or revenue-generating opportunities (e.g., sensor manufacturing).

Consider solutions that address entire product value chain

MedTech companies should consider developing end-to-end solutions that are focused on differentiated sources of value, customer productivity, and patient disease management. These solutions should address all aspects of the MedTech product value chain:


- Capture (sensor)
- Transmission (to analytical engine, whether central or remote)
- Aggregation (of multiple sensor inputs)
- Analysis (through sophisticated algorithms and referencing empirical studies)
- Interpretation and insight
- Monitoring (to see if course is changed)

Addressing the entire product value chain means that an offering cannot be marketed as a commodity. As well, the traditional MedTech revenue model of selling devices at a fixed price will likely need to change to a solutions-based pricing approach.

Conclusion

Smart, connected medical devices are now technologically and economically feasible. As health care shifts from institutional to outpatient and home settings, MedTech companies should consider focusing on opportunities that will likely result in product and market share advantages in this new landscape. The next decade will likely be critical in linking data generated by these smart MedTech devices with data from traditional systems, and integrating that information into everyday practice.

Companies should consider evaluating their portfolios, consider emerging threats and opportunities, develop a clear growth strategy, engage in partnerships and alliances, and begin making investments in technologies and care areas that might position them for an increasingly intelligent future.



Endnotes

1. Alain Charles Enthoven, "Integrated delivery systems: the cure for fragmentation," *The American Journal of Managed Care* 15, no. 10 (2009): pp. 284-290.
2. XPrize foundation is non-profit organization which organizes incentivized competition to stimulate investments in R&D. It launched a \$10 million competition in Jan 2012 to develop a hand-held mobile device for quick medical diagnosis in a consumer-friendly way.
3. Juvenile Diabetes Research Foundation (JDRF), "\$1.9 billion potential healthcare saving for USA with artificial pancreas," June 2011, <https://www.jdrf.org.uk/news/latest-news/19-billion-potential-healthcare-saving-for-usa-with-artificial-pancreas>, accessed February 2015
4. Gordon E. Moore, "Cramming More Components onto Integrated Circuits," *IEEE* 86, no. 1(1998): pp. 82-85, DOI: 10.1109/JPROC.1998.658762.
5. Ray Kurzweil, "The Law of Accelerating Returns," *Kurzweil Accelerating Intelligence*, March 7, 2001, <http://www.kurzweilai.net/the-law-of-accelerating-returns>, accessed November 2014.
6. Ian Steadman, "IBM's Watson is better at diagnosing cancer than human doctors," *Wired* magazine, February 13, 2013, <http://www.wired.co.uk/news/archive/2013-02/11/ibm-watson-medical-doctor>, accessed February, 2015.
7. Stacy Lawrence, "Mayo Clinic Gentag partner to develop movement sensor patches," *Fierce Medical Devices*, March 4, 2015, <http://www.fiercemedicaldevices.com/story/mayo-clinic-gentag-partner-develop-movement-sensor-patches/2015-03-04>, accessed March, 2015.
8. Dave Evans, "Top 25 Technology Predictions," *Cisco IBSG Innovations Practice*, https://www.cisco.com/web/about/ac79/docs/Top_25_Predictions_121409rev.pdf, accessed November, 2014.
9. The computing metric measures the vendor cost associated with putting one million transistors on a semiconductor.
10. Christopher Mims, "How making microchips 3D could unleash an age of cognitive computing," March 21, 2013, <http://qz.com/65689/how-making-microchips-3d-could-unleash-an-age-of-cognitive-computing/>, accessed February, 2015.
11. The Digital Storage metric measures the vendor cost associated with producing 1 GB of digital storage.
12. The Bandwidth metric measures the vendor cost associated with producing gigabit Ethernet/fiber ("GbE-Fiber") as deployed in data centers.
13. Phys.org, "One petabit per second fiber transmission over 50 km," September 21, 2012, <http://phys.org/news/2012-09-petabit-fiber-transmission-km.html>, accessed November, 2014.
14. Scott Reeves, "Pros and cons of using femtocells," *Tech Republic*, November 11, 2013, <http://www.techrepublic.com/blog/data-center/pros-and-cons-of-using-femtocells/#>, accessed November, 2014.
15. Tim Wogan, "New tuner could bring terahertz to the masses," *PhysicsWorld*, June 12, 2012, <http://physicsworld.com/cws/article/news/2012/jun/12/new-tuner-could-bring-terahertz-to-the-masses>, accessed November, 2014.
16. Google, Inc., "What is Project Loon?" <http://www.google.com/loon/>, accessed November, 2014.
17. comScore, "comScore reports January 2013 U.S. smartphone subscriber market share," March 06, 2013, http://www.comscore.com/Insights/Press_Releases/2013/3/comScore_Reports_January_2013_U.S._Smartphone_Subscriber_Market_Share, accessed November, 2014.
18. Ray Kurzweil, "The Intelligent Universe," *Edge*, November 05, 2002, <http://edge.org/conversation/the-intelligent-universe>, accessed December 2014.
19. Ray Kurzweil, "The Human Machine Merger: Why We Will Spend Most of Our Time in Virtual Reality in the Twenty-first Century," *Kurzweil Accelerating Intelligence*, August 29, 2001, <http://www.kurzweilai.net/the-human-machine-merger-why-we-will-spend-most-of-our-time-in-virtual-reality-in-the-twenty-first-century>, accessed March, 2015.
20. John Hagel III, John Seely Brown, and Duleesha Kulasoorya, "The 2011 Shift Index Measuring the forces of long-term change," *Deloitte Center for the Edge*, 2011, http://www.deloitte.com/assets/dcom-unitedstates/local%20assets/documents/us_tmt_2011shiftindex_111011.pdf, accessed March, 2015.
21. Hans Moravec, "When will computer hardware match the human brain," *Journal of Evolution and Technology*, December, 1997, <http://www.transhumanist.com/volume1/moravec.htm>, accessed December, 2014.
22. Rajeev Ronanki and David Steier, "Cognitive analytics Tech Trends 2014," *Deloitte University Press*, February 21, 2014, <http://dupress.com/articles/2014-tech-trends-cognitive-analytics/>, accessed March, 2015.
23. Ibid.
24. Lindsey Dunn, "Carilion Clinic Using Watson Technology to Identify At-Risk Patients," *Becker's Health IT and CIO* review, April 29, 2014, <http://www.beckershospitalreview.com/healthcare-information-technology/carilion-clinic-using-watson-technology-to-identify-at-risk-patients.html>, accessed March, 2015.
25. IBM Corp, "University of Ontario Institute of Technology, Leveraging key data to provide proactive patient care," December, 2010, <http://www.ibmbigdatahub.com/sites/default/files/document/ODC03157USEN.PDF>, accessed March, 2015.
26. Deloitte Center for Health Solutions, 2015 Survey of U.S. Health Care Consumer.
27. Harry Greenspun and Sheryl Coughlin, *Health in an mWorld*, *Deloitte Center for Health Solutions*, 2012, <http://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-mhealth-in-an-mworld-103014.pdf>, accessed March, 2015.
28. Center for Disease Control and Prevention, "National diabetes statistics report: estimates of diabetes and its burden in the United States," 2014, <http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf>, accessed April, 2015.
29. Jonathan C Javitt, "Deployment of an mHealth patient monitoring solution for diabetes: improved glucose monitoring leads to reduction in medical expenditure," *U.S. Endocrinology*, November 27, 2013, pp. 119-123, <http://www.activecare.com/downloads/US%20Endocrinology%20Winter%202014.pdf>, accessed December, 2014.
30. Peggy Albright, "Sensor based apps offer lots of potential but are hindered by fragmentation," *Fierce Developer*, April 20, 2012, <http://www.fiercedev.com/story/sensor-based-apps-offer-lots-potential-are-hindered-fragmentation/2012-04-20>, accessed January, 2015.
31. Brian Buntz, "Preparing for the acute care environment of the (near) future with wireless," *Qmed*, January 02, 2013, <http://www.qmed.com/mpmn/medtechpulse/preparing-acute-care-environment-near-future-wireless?page=4>, accessed March, 2015.
32. Center for technology and aging, "Technologies for Improving Post-Acute Care Transitions," September, 2010, <http://www.techandaging.org/PACTdraftPositionPaper.pdf>, accessed March, 2015.
33. Ibid.
34. Molly Joel Coye, Ateret Haselkorn, and Steven DeMello, "Remote Patient Management: Technology Enabled Innovation And Evolving Business Models For Chronic Disease Care," *Health Affairs* 28, no. 1(2009): pp. 126-135, DOI: 10.1377/hlthaff.28.1.126.
35. Alex H. Krist, Steven H. Woolf, Stephen F. Rothemich, and Robert E. Johnson, "Interactive Preventive Health Record to Enhance Delivery of Recommended Care: A Randomized Trial," *Annals of family medicine*, 10 (2012): pp. 312-319, DOI: 10.1370/afm.1383.
36. *Deloitte 2015 Global life sciences outlook*, <http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-life-sciences-report.pdf>, accessed March 2015.
37. Glenn Snyder, Faruk Abdullah, and Michael Lefferts, "The three rules in medical technology," *Deloitte University Press*, December 11, 2013, <http://dupress.com/articles/three-rules-medical-technology/>, accessed March, 2015.



Contacts in Switzerland

Robert Reppas

Lead Partner, Life Sciences
Deloitte Consulting AG
Switzerland
rreppas@deloitte.ch

Andreas Vogt

Partner, Life Sciences
Deloitte Consulting AG
Switzerland
andvogt@deloitte.ch

Murielle Launay

Senior Manager, Med Tech Segment
Deloitte AG
Switzerland
mlaunay@deloitte.ch



Authors

Glenn H. Snyder

Principal
Med Tech Segment Leader
Deloitte Consulting LLP
gsnyder@deloitte.com

Sunandan Bandyopadhyay

Senior Analyst
Deloitte Center for Health Solutions
Deloitte Support Services India Pvt. Ltd.
subandyopadhyay@deloitte.com



Acknowledgements

We would like to thank Juliet Wegener, Omid M. Akhavan, Michael E. Raynor, Mark J. Cotteleer, Brenna Sniderman, Mohinder Sutrave, Balaji Bondili, Jeff Ford, Kathryn Robinson, Larisa Layug, and Ujval Kondragunta for their contributions to this report.



Contact information

To learn more about our life sciences practice in Switzerland visit: www.deloitte.com/ch/lifesciences

Visit www.deloitte.com/centerforhealthsolutions to find out more about the Center for Health Solutions in the US.

Deloitte Center for Health Solutions

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor.

Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

As used in this document, "Deloitte" means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/ch/about for a detailed description of the legal structure of DTTL and its member firms.

Deloitte AG is a subsidiary of Deloitte LLP, the United Kingdom member firm of DTTL.

Deloitte AG is an audit firm recognised and supervised by the Federal Audit Oversight Authority (FAOA) and the Swiss Financial Market Supervisory Authority (FINMA).

This publication has been written in general terms and therefore cannot be relied on to cover specific situations; application of the principles set out will depend upon the particular circumstances involved and we recommend that you obtain professional advice before acting or refraining from acting on any of the contents of this publication. Deloitte AG would be pleased to advise readers on how to apply the principles set out in this publication to their specific circumstances. Deloitte AG accepts no duty of care or liability for any loss occasioned to any person acting or refraining from action as a result of any material in this publication.

© 2015 Deloitte AG. All rights reserved.

Designed and produced by The Creative Studio at Deloitte, Zurich. J1447